Reduction of cisplatin dosage by ZD 1839

Anticancer Research

Volumn 25, Issue 6 B, 2005, Pages 3985-3988

  Hambek, Markus ^a   Baghi, Mehran ^a   Strebhard, Klaus ^a   Baumann, Helena ^a   Gstöttner, Wolfgang ^a   Knecht, Rainald ^a,b  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Cisplatin; SCCHN; ZD 1839

Indexed keywords

CISPLATIN; GEFITINIB; LACTATE DEHYDROGENASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DOSE REDUCTION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CISPLATIN; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HEAD AND NECK NEOPLASMS; HUMANS; INHIBITORY CONCENTRATION 50; L-LACTATE DEHYDROGENASE; PROTEIN KINASE INHIBITORS; QUINAZOLINES; TETRAZOLIUM SALTS; THIAZOLES;

EID: 27944472598     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Liverpool Head and Neck Oncology Group: A phase III randomised trial of cisplatinum, methotrexate, cisplatinum methotrexate and cisplatinum 5-FU in end stage squamous carcinoma of the head and neck. Br J Cancer 61: 311-315, 1990.
2. Clavel M, Vermorken JB, Cognetti F et al: Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck: a phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 5: 521-526, 1994.
3. Forastiere AA, Metch B, Schuller DE et al: Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 10: 1245-1251, 1992.
4. Forastiere AA, Leong T, Rowinsky E et al: Phase III comparison of high-dose paclitaxel cisplatin granulocyte colony-stimulating factor versus low-dose paclitaxel cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. J Clin Oncol 19: 1088-1095, 2001.
5. Jacobs C, Lyman G, Velez-Garcia E et al: A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10: 257-263, 1992.
6. Schrijvers D, Johnson J, Jiminez U et al: Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer: Head and Neck Interferon Cooperative Study Group. J Clin Oncol 16: 1054-1059, 1998.
7. Cohen S, Carpenter G and King L Jr: Epidermal growth factor-receptor protein kinase interactions: co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. J Biol Chem 255: 4834-4842, 1980.
8. Olayioye MA, Neve RM, Lane HA et al: The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19: 3159-3167, 2000.
9. Kolch W: Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 351: 289-305, 2000.
10. Baselga J and Averbuch SD: ZD1839 ('Iressa') as an anticancer agent. Drugs 60(suppl): 33-40, 2000.
11. Zwick E, Bange J and Ullrich A: Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol Med 8: 17-23, 2002.
12. Busse D, Doughty RS, Ramsey TT et al: Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity. J Biol Chem 275: 6987-6995, 2000.
13. Ciardiello F and Tortora G: A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7: 2958- 2970, 2001.